Z17.4
Combined receptor status
Clinical Classification Guidelines
Clinical Notes
Assign a code from subcategory Z17.4- when only a combined receptor status is documented
Medical Intelligence & Overview
ICD-10 code Z17.4 is used to indicate instances where a patient's medical records include a documented combined receptor status. In medical practice, receptor status refers to the assessment of specific proteins on the surface of cancer cells, which can influence treatment decisions and prognosis. When clinicians evaluate certain types of cancer, such as breast cancer, they often determine the presence or absence of receptors like estrogen, progesterone, and HER2. A combined receptor status summarizes these findings into a single, comprehensive report. This code is specifically assigned when only this combined receptor information is documented in the patient's medical records, without additional detailed receptor status data.
Causes & Symptoms
Clinical Causes: Diagnosis of cancers, especially breast cancer, where receptor testing is performed Medical documentation noting the combined receptor status during pathology reports Follow-up assessments documenting receptor status to guide treatment planning Compiling comprehensive receptor information for medical coding and billing purposes
Key Symptoms: There are no direct symptoms associated with the coding of receptor status, as it is a diagnostic and documentation process Receptor status findings influence symptoms and disease course, but the code itself pertains to medical records, not clinical presentation
Diagnostic & Treatment
Diagnosis Path: The diagnosis related to Z17.4 originates from laboratory testing and pathological assessment. Tests such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are used to determine receptor presence. A combined receptor status report summarizes the results of these tests, indicating whether various receptors are positive or negative. The documentation is then reviewed by clinicians and coders to assign the proper ICD-10 code, Z17.4, when only this comprehensive status is recorded.
Treatment Protocols: While the specific treatment varies based on the receptor status findings, the coding itself does not influence therapeutic decisions. Typically, treatment options for cancers with known receptor statuses include hormone therapies, targeted therapies, chemotherapy, or a combination of these. The documentation of the combined receptor status helps guide these decisions, but the coding is used primarily for record-keeping and billing purposes rather than treatment planning.
Clinical Advice & FAQs
Billing Guidance
Is Z17.4 a billable ICD-10 code?
Yes, Z17.4 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.4?
Clinical documentation must specify the nature of Combined receptor status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference